A detailed history of Vanguard Group Inc transactions in Cv Rx, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 663,503 shares of CVRX stock, worth $10.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
663,503
Previous 594,312 11.64%
Holding current value
$10.2 Million
Previous $10.8 Million 26.49%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$6.49 - $19.2 $449,049 - $1.33 Million
69,191 Added 11.64%
663,503 $7.96 Million
Q1 2024

May 10, 2024

BUY
$17.99 - $30.49 $570,642 - $967,142
31,720 Added 5.64%
594,312 $10.8 Million
Q4 2023

Feb 14, 2024

BUY
$11.67 - $33.01 $146,621 - $414,737
12,564 Added 2.28%
562,592 $17.7 Million
Q3 2023

Nov 14, 2023

BUY
$13.56 - $18.47 $23,241 - $31,657
1,714 Added 0.31%
550,028 $8.34 Million
Q2 2023

Aug 14, 2023

BUY
$8.57 - $15.44 $471,187 - $848,906
54,981 Added 11.14%
548,314 $8.47 Million
Q1 2023

May 15, 2023

BUY
$7.08 - $19.4 $326,373 - $894,301
46,098 Added 10.31%
493,333 $4.6 Million
Q4 2022

Feb 10, 2023

BUY
$8.94 - $18.35 $133,340 - $273,690
14,915 Added 3.45%
447,235 $8.21 Million
Q3 2022

Nov 14, 2022

SELL
$6.12 - $9.5 $73,733 - $114,456
-12,048 Reduced 2.71%
432,320 $4.03 Million
Q2 2022

Aug 12, 2022

SELL
$4.7 - $7.22 $91,964 - $141,273
-19,567 Reduced 4.22%
444,368 $2.67 Million
Q1 2022

May 13, 2022

BUY
$5.62 - $12.37 $391,815 - $862,411
69,718 Added 17.69%
463,935 $2.78 Million
Q4 2021

Feb 14, 2022

SELL
$10.65 - $18.61 $3.09 Million - $5.4 Million
-290,074 Reduced 42.39%
394,217 $4.82 Million
Q3 2021

Nov 12, 2021

BUY
$14.65 - $26.07 $9.31 Million - $16.6 Million
635,531 Added 1303.39%
684,291 $11.3 Million
Q2 2021

Aug 13, 2021

BUY
$28.0 - $28.0 $1.37 Million - $1.37 Million
48,760 New
48,760 $1.37 Million

Others Institutions Holding CVRX

About CVRx, Inc.


  • Ticker CVRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 20,576,200
  • Market Cap $317M
  • Description
  • CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The co...
More about CVRX
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.